Healthcare provider profile · identity verified

Manish Govind Patel, MD

Internal Medicine · MOORESVILLE, NC · NPI 1750362950

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	389	104
Losartan Potassium	Losartan Potassium	277	82
Amlodipine Besylate	Amlodipine Besylate	206	60
Atorvastatin Calcium	Atorvastatin Calcium	205	65
Omeprazole	Omeprazole	197	56
Metformin Hcl Er	Metformin Hcl	169	53
Trazodone Hcl	Trazodone Hcl	121	33
Rosuvastatin Calcium	Rosuvastatin Calcium	116	37
Alprazolam	Alprazolam	106	31
Glipizide Er	Glipizide	103	23
Pantoprazole Sodium	Pantoprazole Sodium	102	30
Lisinopril	Lisinopril	100	30
Metoprolol Succinate	Metoprolol Succinate	95	25
Potassium Chloride	Potassium Chloride	95	26
Gabapentin	Gabapentin	94	27
Hydrochlorothiazide	Hydrochlorothiazide	88	29
Metformin Hcl	Metformin Hcl	88	23
Mounjaro	Tirzepatide	85	13
Tamsulosin Hcl	Tamsulosin Hcl	83	27
Escitalopram Oxalate	Escitalopram Oxalate	79	19
Simvastatin	Simvastatin	76	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	74	22
Meloxicam	Meloxicam	72	24
Metoprolol Tartrate	Metoprolol Tartrate	72	21
Zolpidem Tartrate	Zolpidem Tartrate	61	19
Progesterone	Progesterone, Micronized	60	17
Ozempic	Semaglutide	59	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	58	20
Eliquis	Apixaban	57	12
Duloxetine Hcl	Duloxetine Hcl	56	16
Allopurinol	Allopurinol	53	15
Donepezil Hcl	Donepezil Hcl	53	14
Valsartan	Valsartan	53	18
Pioglitazone Hcl	Pioglitazone Hcl	50	12
Furosemide	Furosemide	47	15
Famotidine	Famotidine	44	13
Liothyronine Sodium	Liothyronine Sodium	44	14
Diazepam	Diazepam	43	11
Fluoxetine Hcl	Fluoxetine Hcl	43	13
Jardiance	Empagliflozin	43	suppressed
Atenolol	Atenolol	41	12
Ezetimibe	Ezetimibe	39	14
Estradiol	Estradiol	38	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	38	11
Synthroid	Levothyroxine Sodium	37	suppressed
Testosterone Cypionate	Testosterone Cypionate	37	17
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Propranolol Hcl Er	Propranolol Hcl	36	13
Sertraline Hcl	Sertraline Hcl	36	11
Tizanidine Hcl	Tizanidine Hcl	35	suppressed
Carvedilol	Carvedilol	34	12
Tramadol Hcl	Tramadol Hcl	32	12
Bupropion Xl	Bupropion Hcl	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	suppressed
Clonazepam	Clonazepam	29	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	29	23
Farxiga	Dapagliflozin Propanediol	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Hydrocortisone	Hydrocortisone	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Valacyclovir	Valacyclovir Hcl	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Lorazepam	Lorazepam	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	16
Cephalexin	Cephalexin	20	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	15
Fluconazole	Fluconazole	20	15
Mirtazapine	Mirtazapine	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Glipizide	Glipizide	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Prednisone	Prednisone	19	17
Pregabalin	Pregabalin	19	suppressed
Glimepiride	Glimepiride	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Tresiba Flextouch U-200	Insulin Degludec	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Methylprednisolone	Methylprednisolone	16	14
Ramipril	Ramipril	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Temazepam	Temazepam	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Np Thyroid	Thyroid,pork	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Torsemide	Torsemide	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Invokana	Canagliflozin	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	12	11
Azithromycin	Azithromycin	12	12
Myrbetriq	Mirabegron	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error